Eric Schmidt
Analyst
Cowen and Company
Analyst
Cantor
Analyst
Cantor Fitzgerald
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Eric Schmidt
Eric Schmidt is recorded as Analyst at Cowen and Company, Analyst at Cantor and Analyst at Cantor Fitzgerald. Earlier roles on record: CFO at Allogene Therapeutics, Inc. (ALLO) until August 2, 2023 and Board Member at Relmada Therapeutics, Inc. (RLMD) until September 5, 2023. Relmada Therapeutics, Inc. reported in an 8-K filed September 6, 2023 that Eric Schmidt resigned as member of the Board of Directors, effective September 5, 2023. Allogene Therapeutics, Inc. reported in an 8-K filed June 14, 2023 that Eric Schmidt resigned as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 2, 2023. The proxy statement of Allogene Therapeutics, Inc. reports total compensation of $5,279,677 for Eric Schmidt in fiscal 2022, including a base salary of $490,000. Disclosed compensation is on record for 5 fiscal years. Eric Schmidt has spoken on 21 earnings calls and 3 other investor events across 7 companies, most recently for Agios Pharmaceuticals, Inc. on September 9, 2026.
“On September 5, 2023, Eric Schmidt, a member of the Board of Directors (the "Board") of Relmada Therapeutics, Inc. (the "Company"), notified the Company that he would resign from the Board, effective immediately.”
“On June 9, 2023, Eric Schmidt, Ph.D., the Chief Financial Officer, principal financial officer and principal accounting officer of Allogene Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign, effective at the close of business on August 2, 2023, to spend more time with his family.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Cowen and Company
Analyst
Source not stated
Current -
Cantor
Analyst
Source not stated
Current -
Cantor Fitzgerald
Analyst
Source not stated
Current -
Start not stated–2023-08-02
-
Start not stated–2023-09-05
-
Start not stated–2023-09-05
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $490,000 | $5,279,677 |
| 2021 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $475,000 | $3,458,962 |
| 2020 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $440,000 | $2,483,819 |
| 2019 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $425,000 | $3,460,066 |
| 2018 | Allogene Therapeutics, Inc. (ALLO) | Chief Financial Officer | $201,232 | $2,588,989 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.